111 results on '"Verdonschot, Job A.J."'
Search Results
2. Papillary Muscle Delayed Hyperenhancement: Prevalence and Clinical Implications in a Large Population With Dilated Cardiomyopathy
3. Clonal Hematopoiesis Has Prognostic Value in Dilated Cardiomyopathy Independent of Age and Clone Size
4. Left Atrial Function in Patients with Titin Cardiomyopathy
5. Immunomodulation of Myocardial Fibrosis
6. Phenotypic variability of filamin C–related cardiomyopathy: Insights from a novel Dutch founder variant
7. Multicenter clinical and functional evidence reclassifies a recurrent noncanonical filamin C splice-altering variant
8. Clustering of Cardiac Transcriptome Profiles Reveals Unique: Subgroups of Dilated Cardiomyopathy Patients
9. Natural History of MYH7-Related Dilated Cardiomyopathy
10. Clinical Risk Score to Predict Pathogenic Genotypes in Patients With Dilated Cardiomyopathy
11. Precision Phenotyping of Dilated Cardiomyopathy Using Multidimensional Data
12. Left Atrial Strain Has Superior Prognostic Value to Ventricular Function and Delayed-Enhancement in Dilated Cardiomyopathy
13. The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial
14. The next era of gene‐specific clinical care in patients with dilated cardiomyopathy.
15. Metabolic Profiling Associates with Disease Severity in Nonischemic Dilated Cardiomyopathy
16. Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort.
17. Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial
18. Cardiac Inflammation Impedes Response to Cardiac Resynchronization Therapy in Patients with Idiopathic Dilated Cardiomyopathy
19. Clonal Hematopoiesis Has Prognostic Value in Dilated Cardiomyopathy Independent of Age and Clone Size
20. Clinical Outcome in KLHL24 Cardiomyopathy
21. Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial.
22. Distinct Cardiac Transcriptomic Clustering in Titin and Lamin A/C-Associated Dilated Cardiomyopathy Patients
23. Multicenter Clinical and Functional Evidence Reclassifies a Recurrent Non-canonical Filamin C Splice-altering Variant
24. Urinary Proteomic Signature of Mineralocorticoid Receptor Antagonism by Spironolactone: Evidence from the Randomized-Controlled HOMAGE and PRIORITY Trials
25. Prevalence and Clinical Consequences of Multiple Pathogenic Variants in Dilated Cardiomyopathy
26. Left Atrial Strain Is an Independent Predictor of New-Onset Atrial Fibrillation in Dilated Cardiomyopathy
27. Titin Allelic Expression and Protein Processing Pathways in Early-Stage Dilated Cardiomyopathy Patients With Truncating Titin Variants
28. Reply
29. Myocardial Fibrosis Assessment Using T1 and ECV Mapping With Histologic Validation in Chronic Dilated Cardiomyopathy
30. Natural History of MYH7-Related Dilated Cardiomyopathy
31. Dyskalemia in people at increased risk for heart failure: findings from the heart ‘OMics’ in AGEing (HOMAGE) trial
32. Clinical Phenotype and Genotype Associations With Improvement in Left Ventricular Function in Dilated Cardiomyopathy
33. Multicenter clinical and functional evidence reclassifies a recurrent noncanonical filamin C splice-altering variant.
34. A machine learning‐derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: Findings from the HOMAGE trial.
35. Dynamic Ejection Fraction Trajectory in Patients With Dilated Cardiomyopathy With a Truncating Titin Variant
36. Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma:a systematic review
37. The HFA‐PEFF score identifies ‘early‐HFpEF’ phenogroups associated with distinct biomarker profiles
38. Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial
39. Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: a systematic review of 2010-2020
40. Improving diagnosis and risk stratification across the ejection fraction spectrum: the Maastricht Cardiomyopathy registry
41. The effect of spironolactone in patients with obesity at risk for heart failure: proteomic insights from the HOMAGE trial
42. Clinical impact of re-evaluating genes and variants implicated in dilated cardiomyopathy
43. The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial.
44. A global longitudinal strain cut‐off value to predict adverse outcomes in individuals with a normal ejection fraction
45. The combination of carboxy‐terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy – A multilevel assessment of myocardial fibrosis in dilated cardiomyopathy
46. A mutation update for the FLNC gene in myopathies and cardiomyopathies
47. Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double‐blind, randomized, placebo‐controlled clinical trial
48. Implications of Genetic Testing in Dilated Cardiomyopathy
49. Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review
50. Value of Speckle Tracking–Based Deformation Analysis in Screening Relatives of Patients With Asymptomatic Dilated Cardiomyopathy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.